GlassScriptPhysician profile
Kimberly S Huff
NPI 1528799749
$5,316.97
in general payments reported to CMS, 2019-2025
23 companies · $1,330 in 2025
The $1,330 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $479 · 2023: $1,461 · 2024: $2,047 · 2025: $1,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,838.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,170.25 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $629.76 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $421.64 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $354.46 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $328.11 | 2022-2025 | Azstarys |
| Lundbeck LLC | $227.78 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $218.38 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $205.72 | 2023-2024 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $158.62 | 2022-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $154.23 | 2023-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $100.89 | 2023-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Indivior INC. | $64.49 | 2022-2023 | Perseris |
| Tris Pharma INC | $63.52 | 2022-2024 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $33.71 | 2023-2025 | Bexsero, Pediarix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $32.40 | 2024-2025 | Cobenfy, Eliquis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $30.26 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Vanda Pharmaceuticals INC. | $28.35 | 2022 | |
| Collegium Pharmaceutical, INC. | $19.94 | 2025 | Jornay Pm |
| Alnylam Pharmaceuticals INC. | $18.78 | 2024 | Onpattro |
| Jazz Pharmaceuticals INC. | $15.56 | 2024 | |
| Antares Pharma, INC. | $14.55 | 2022 | |
| Boston Scientific Corporation | $13.53 | 2025 | Wavewriter Alpha Prime 16 |
| Kowa Pharmaceuticals America, INC. | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Huff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.